Clin Psychopharmacol Neurosci.
2025 Nov;23(4):724-727. 10.9758/cpn.25.1284.
Aripiprazole Long-acting Injectable Two-injection Start to Manage Supersensitivity Psychosis: A Case Report
- Affiliations
-
- 1Department of Psychiatry, Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey
- KMID: 2574606
- DOI: http://doi.org/10.9758/cpn.25.1284
Abstract
- Dopamine supersensitivity psychosis (DSP) is characterized by treatment resistance, tardive dyskinesia, and worsening psychotic symptoms due to long-term antipsychotic use. A 52-year-old woman with treatment-resistant schizophrenia and possible DSP continued to experience persistent psychotic symptoms despite high-dose antipsychotic treatment. Through close follow-up, symptom improvement was observed following the gradual reduction of antipsychotic doses and the introduction of the aripiprazole long-acting injectable (LAI) two-injection start regimen. This approach may offer a rapid and effective strategy for stabilizing dopamine receptors in patients with DSP. This case highlights the potential role of aripiprazole LAI in DSP management and symptom improvement in complex clinical presentations.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treating First-episode Psychosis with a Two-injection Start Regimen of Long-acting Aripiprazole in a Person with HIV
- Breakthrough Psychosis and Long-Acting Injectable Antipsychotics
- Clinical Reasoning in the Use of Long-acting Aripiprazole in Psychosis in Bilateral Nephrectomy on Hemodialysis
- First Manic Episode in a Young Woman with Schizophrenia after Initiation of Oral Aripiprazole and Aripiprazole Long-Acting Injection
- Effectiveness of Aripiprazole Long-Acting Injection in Schizophrenia Patients Undergoing Antipsychotic Combination Therapy: A Retrospective Observational Study
